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Abstract
Background: Injection of CD8 T cells primed against immunodominant minor histocompatibility antigens (MiHA) such as H7
a
can eradicate leukemia and solid tumors. To understand why MiHA-targeted T cells have such a potent antitumor effect it is
essential to evaluate their in vivo behavior. In the present work, we therefore addressed two specific questions: what is the
proliferative dynamics of H7
a-specifc T cells in tumors, and do H7
a-specific T cells persist long-term after adoptive transfer?
Methodology/Principal Findings: By day 3 after adoptive transfer, we observed a selective infiltration of melanomas by
anti-H7
a T cells. Over the next five days, anti-H7
a T cells expanded massively in the tumor but not in the spleen. Thus, by day
8 after injection, anti-H7
a T cells in the tumor had undergone more cell divisions than those in the spleen. These data
strongly suggest that anti-H7
a T cells proliferate preferentially and extensively in the tumors. We also found that two host
factors regulated long-term persistence of anti-H7
a memory T cells: thymic function and expression of H7
a by host cells. On
day 100, anti-H7
a memory T cells were abundant in euthymic H7
a-negative (B10.H7
b) mice, present in low numbers in
thymectomized H7
a-positive (B10) hosts, and undetectable in euthymic H7
a-positive recipients.
Conclusions/Significance: Although in general the tumor environment is not propitious to T-cell invasion and expansion,
the present work shows that this limitation may be overcome by adoptive transfer of primed CD8 T cells targeted to an
immunodominant MiHA (here H7
a). At least in some cases, prolonged persistence of adoptively transferred T cells may be
valuable for prevention of late cancer relapse in adoptive hosts. Our findings therefore suggest that it may be advantageous
to target MiHAs with a restricted tissue distribution in order to promote persistence of memory T cells and thereby minimize
the risk of cancer recurrence.
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Introduction
Adoptive transfer of allogeneic T lymphocytes, used primarily for
treatment of hematopoietic malignancies, has met with a remark-
able success rate [1,2]. Accordingly, the so-called graft-versus-
leukemia (GVL) effect represents the most conclusive documenta-
tion that the immune system can cure cancer in humans [1,3,4].
The GVL effect is due mainly, and perhaps exclusively, to
recognition of minor histocompatibility antigens (MiHAs) [1,2,5].
We reported that injection of CD8 T cells primed against the model
immunodominant H7
a MiHA could eradicate not only leukemia
but also melanoma in mouse [6,7]. The chain of events leading to
melanoma eradication by anti-H7
a T cells involves the following
steps [7]. First, primed T cells accumulate at the tumor site. This
initial step depends on interaction between Vla-4 on T cells and
Vcam-1 on tumor blood vessels. Second, local release of IFN-c by
anti-H7
a T cells has two crucial effects: inhibition of tumor
angiogenesis and upregulation of MHC I expression on tumor cells.
Finally, anti-H7
a CD8 T cells undergo antigen-specific granule
exocytosis in the tumor and thereby kill tumor cells. Of note, T cells
specificfora single MiHA,suchasH7
a,neverelicitgraft-versus-host
disease even when their target MiHA is ubiquitously expressed in
recipient tissues and organs [6–8].
To understand why MiHA-targeted T cells are so effective we
deemed it essential to evaluate their in vivo behavior. In the present
work, we therefore addressed two specific questions. First, what is
the proliferative dynamics of H7
a-specifc T cells in the tumor?
This is a critical issue since cancer refractoriness to immunother-
apy is commonly due to failure of T cells to penetrate and
accumulate in the tumors [9–12]. Second, do H7
a-specific T cells
persist long-term, and is protracted T-cell reactivity to H7
a
necessary to prevent tumor recurrence? We report that the
proliferation dynamics of anti-H7
a CD8 T cells is dramatically
different in the tumor compared with the spleen. We present
evidence that the massive accumulation of anti-H7
a in melanomas
is largely due to extensive in situ proliferation. Moreover, we found
that the long-term fate of H7
a-specific T cells was dictated by two
host factors: thymic function and expression of H7
a by normal host
cells. Notably, mice in which anti-H7
a T cells did not persist long-
term (day 100) nevertheless remained tumor-free. Thus, in this
PLoS ONE | www.plosone.org 1 January 2009 | Volume 4 | Issue 1 | e4116model, cure is probably due to eradication of clonogenic tumor
cells rather than to induction of T-cell dependent tumor
dormancy.
Materials and Methods
Mice, Tumor Cells and Statistics
We obtained B10.H7
b(47N)/Sn (B10.H7
b) and C57BL/10J
(B10) mice from the Jackson Laboratory (Bar Harbor, ME) and
the B16.F10 melanoma cell line from the American Type Culture
Collection (Manassas, VA). Mouse care and experimental proce-
dures were performed under approval from the Animal Care
Committees of the University of Montreal and of the Maisonneuve-
Rosemont Hospital. Mice were treated according to the guidelines
of the Canadian Council on Animal Care. Differences between
group means were tested using Student’s t test.
Cell Transplantation and Thymectomy
On day 0, H7
a-positive (B10) and H7
a-negative (B10.H7
b)
recipients received 12 Gy total-body irradiation, 10
7 T cell-
depleted bone marrow cells i.v. and 2610
5 tumor cells s.c. in the
right flank. On day 7, recipients were treated with 5610
7
splenocytes from B10.H7
b donors primed against H7
a. Priming
of B10.H7
b donors against H7
a was performed by i.p. injection of
2610
7 B10 spleen cells 14 days prior to adoptive transfer. Tumor
size was measured every 48 h and we sacrificed mice when the
Figure 1. Experimental model and study design. Melanoma-bearing mice received splenocytes primed against H7
a on day 7. Short-term
studies on T-cell proliferation kinetics were performed from day 10 to day 15, and long-term studies on memory T cells were initiated on day 100.
doi:10.1371/journal.pone.0004116.g001
Fate of H7
a-Specific T Cells
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challenged cured mice with 2610
5 B16.F10 melanoma cells s.c.
Thymectomy were performed as previously described [13].
Cell Staining with Antibodies and Tetramers
We purchased antibodies specific for the following molecules:
CD8 (53-6.7), from BD Pharmingen (San Jose, CA) and CD44 (11-
0441), from eBioscience (San Diego, CA). We obtained phycoer-
ythrin-labeled H7
a-H2D
b tetramers from the tetramer core facility
of the Canadian Network for Vaccines and Immunotherapeutics
(Montreal, QC, Canada). Cells were stained as previously described
and were analyzed on a FACSCalibur using the CellQuest program
(BD Biosciences, San Jose, CA) [14,15].
Assessment of T-Cell Proliferative Dynamics from CFSE
Profiles
We labeled splenocytes from B10.H7
b female mice (immunized
on day 27 against H7
a) with CFSE (Molecular Probes,
Burlington, ON, Canada) as previously described [16,17]. Briefly,
splenocytes were suspended at a concentration of 5610
7 cells/ml
in Hanks’ balanced salt solution. After warming to 37uC, CFSE
was added at a concentration of 5 mM for 15 minutes, followed by
addition of ice-cold RPMI media and cell recovery by centrifu-
gation. Donor cells were subsequently injected i.v. into the tail vein
of recipient mice. Before analysis, we stained cell suspensions
containing CFSE-labeled cells with anti-CD8 antibody and H7
a-
H2D
b tetramers. Division peaks (as determined by CFSE-intensity)
were labeled from 0 to n. Since a single T cell dividing n times will
generate 2
n daughter cells, if the total number of T cells which
have divided three times (n=3) is eight, then exactly one precursor
had to divide three times to generate these eight cells (2
3=8)
[17,18]. Making use of this mathematical relationship, the number
of T cells that have divided was extrapolated from the number of
daughters under each division peak, and the total number of
mitotic events was calculated as described [16,19]. The prolifer-
ative burst size (number of daughter cells generated by a dividing
T-cell ‘‘precursor’’) was obtained by dividing the total number of
mitoses by the number of precursors that had divided [19].
Results
Experimental Model (Fig. 1)
On day 0, H7
a-positive (B10) and H7
a-negative (B10.H7
b) mice
received 12 Gy total-body irradiation, 10
7 T cell-depleted bone
marrow cells i.v. and 2610
5 B16.F10 melanoma cells (H7
a-
positive) s.c. On day 7, we treated mice by injection of 5610
7
splenocytes from B10.H7
b female immunized against H7
a 14 days
prior to adoptive transfer. Splenocyte suspensions (5610
7 cells)
from donors primed against H7
a contained 2.560.3610
5 H7
a
tetramer-positive CD8 T cells (data not shown). We have
previously reported the gene expression profile and cell surface
phenotype H7
a tetramer-positive CD8 T cells primed under those
conditions [7,15]. CD8 T cells supplied with CD4 help at the time
of initial priming generate more efficient effector cells upon
secondary challenge [20,21]. Thus, as in previous studies [6,7], we
used B10.H7
b female mice primed against B10 male cells as a
source of anti-H7
a CD8 T cells. This immunization scheme leads
to the expansion of anti-HY CD4 T cells and of anti-H7
a CD8 T
cells in donor mice (immunodomination prevents expansion of
anti-HY CD8 T cells) [22–24]. We used only female mice as
recipients. Thus, following adoptive transfer only anti-H7
a CD8 T
cells could encounter their cognate Ag in recipients because both
recipients and tumor cells are HY-negative. Our model displays
two features that make it relevant as a pre-clinical paradigm: i) our
protocol involves a therapeutic rather than prophylactic setting
[25]; ii) alike most spontaneous human tumors, B16.F10 cells do
not express MHC II and display only low levels of MHC I
molecules [26]. We displayed in Fig. 1 the overall study design and
the timing of short-term and long-term studies whose results are
presented in Fig. 2–3 and Fig. 4, 5, 6, respectively.
Proliferation Kinetics of H7
a-Specific CD8 T Cells
The outcome of adoptive immunotherapy is presumably dictated
by the proliferative dynamics of both tumor cells and tumor
infiltrating T cells. In the first set of experiments, we therefore
sought to determine the rate of accumulation and proliferation of
H7
a-specific T cells in the tumor at early time points after adoptive
transfer. To this end, anti-H7
a donor cells were stained with CFSE
before injection in B10 recipients on day 7. We sacrificed mice on
day 10, 13 and 15 (that is, day 3, 6 and 8 after adoptive transfer) and
prepared cells suspensions from tumors and spleens to evaluate T-
cell accumulation and mitotic behavior. Non-specific labeling with
H7
a tetramers, as determined by staining naı ¨ve B10 or B10.H7
b
CD8 T cells, was #0.04% (data not shown). At each time point, the
proportion of CD8 T cells that were H7
a tetramer-positive was <1–
2% in the spleen but <80–90% in the tumor (Fig. 2A). Thus, as
early as day 10 (day 3 after adoptive transfer), we observed a
selective accumulation of H7
a-specific T cells in the tumors.
Between day 10 and day 15, the absolute number of H7
a-specific T
cells remained relatively stable in the spleen but increased <8.5-fold
in the tumor (Fig. 2B and 3B).
The expansion in the number of intratumoral H7
a-specific
CD8
+ T cells could be due to their proliferation in situ or their
recruitment from secondary lymphoid organs. To investigate this
issue, we analyzed the CFSE content of H7
a tetramer-positive T
cells present in the spleen and the tumor. The CFSE content
decreases by 50% after each cell division. The vast majority of
H7
a-specific T cells harvested on day 10 had underwent 0 or 1
mitosis following adoptive transfer (Fig. 3A). From day 10 to 15,
the mean CFSE content of anti-H7
a T cells decreased much more
rapidly in the tumor than in the spleen (Fig. 3A). By day 15, all
Figure 2. Anti-H7
a T cells accumulate in the tumor. We treated
B10 recipient mice as described in Fig. 1. Cell suspensions from their
spleen and tumor were obtained on day 10, 13 and 15, and stained with
H7
a tetramers and anti-CD8 antibody. A) Proportion and B) absolute
numbers of H7
a tetramer-positive CD8 T cells in 3–5 mice studied at
each time point. * P,0.01; 1 P,0.001.
doi:10.1371/journal.pone.0004116.g002
Fate of H7
a-Specific T Cells
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a T cells harvested from the tumor had divided at least
once while a substantial number of anti-H7
a T cells in the spleen
had not (Fig. 3A). Using equations developed by Turka et al.
[17,19] we calculated the proliferative burst size and the doubling
time of H7
a tetramer-positive T cells (Fig. 3). The proliferative
burst size corresponds to the number of daughter cells generated
by a dividing T-cell ‘‘precursor’’, and the doubling time represents
the time required for the average T cell to achieve a single cell
division. Our calculations are based on the assumption that H7
a-
specific T cells present in one site (spleen or tumor) on day 15
derive from H7
a-specific T cells that had seeded this particular site
by day 10. On day 15, H7
a-specific T cells in the tumor displayed
a greater burst size (<3.5-fold) and shorter doubling time (<3-fold)
than H7
a-specific T cells in the spleen (Fig. 3B).
Our studies on the proliferation kinetics of H7
a-specific CD8 T
cells show that H7
a-specific T cells found in the tumor and spleen
have different mitotic histories: H7
a-specific T cells in the tumor
have undergone more cell divisions that those in the spleen (Fig. 3).
These data suggest that the massive expansion H7
a-specific T cells
found in the tumor, but not the spleen, reflects their intratumoral
proliferation.
Two Host Factors Regulate Long-Term Persistence of
H7
a-Specific Memory T Cells
In order to determine whether H7
a-specific T cells persisted
long-term following adoptive transfer, we assessed the numbers of
H7
a tetramer
+ CD8 T cells present on day 100 in the spleen and
bone marrow of euthymic mice successfully treated for melanoma
(as shown in Fig. 1). We paid special attention to the bone marrow
because it is a preferential homing site for memory T cells, and
memory CD8 T cells proliferate more extensively in the bone
marrow than they do in either secondary lymphoid or extra-
lymphoid organs [27]. Since H7
a expression by host cells might
impinge on long-term persistence of H7
a-specific T cells, we
studied the fate of primed H7
a-specific T cells transferred in B10
and B10.H7
b hosts. The salient finding was that significant
numbers of H7
a-specific T cells were found in B10.H7
b but not in
B10 hosts (P,0.001; Fig. 4). The sole difference between these two
strains of mice is that H7
a MiHA is ubiquitously expressed in B10
mice, but absent in B10.H7
b mice [6,28,29]. Thus, when
confronted with ubiquitous expression of their cognate antigen,
H7
a-targeted T cells underwent apoptosis or replicative exhaus-
tion. As expected for memory T cells, about 98% of anti-H7
a T
Figure 3. Evaluation of T-cell proliferative dynamics from CFSE profiles. B10 recipient were treated as in Fig. 1. A) One representative
example of the CFSE profiles observed at each time point (gated on CD8
+ H7
a tetramer
+ T cells) in the spleen and tumor. Numbers in the upper right
corner of each panel represent the percentage of undivided cells (that is, cells showing the highest levels of CFSE). B) Mean (6SD) burst size, doubling
time and expansion of H7
a-specific T cells between day 10 and day 15 in the spleen and tumor. The proliferative burst size and doubling time of anti-
H7
a T cells were calculated as described in materials and methods. Expansion corresponds to the mean number of cells on day 15/mean number of
cells on day 10. Each group contained 3–5 mice. * P,0.001 (spleen vs. tumor).
doi:10.1371/journal.pone.0004116.g003
Fate of H7
a-Specific T Cells
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hi. Consistent with the fact that the bone marrow
is a preferential homing site for memory T cells [27,30], the
frequency of H7
a-specific T cells was higher in the bone marrow
than the spleen of B10.H7
b mice (P,0.01).
Naı ¨ve and memory CD8 T cells may compete for cytokines that
regulate lymphocyte survival and proliferation [31]. We therefore
asked whether in the absence of thymic output, anti-H7
a memory
T cells would persist long-term in B10 hosts. To test this, we
evaluated the persistence of H7
a-specific memory T cells in
euthymic vs. thymectomized H7
a-positive (B10) hosts. Significant
numbers of H7
a-specific memory T cells were present on day 100
in thymectomized B10 hosts (P,0.01 relative to euthymic B10
hosts; Fig. 4). Thus, anti-H7
a T cells can persist long-term in B10
hosts in the absence of naı ¨ve T cell production by the thymus. We
conclude that two host factors regulated persistence of anti-H7
a
memory T cells: thymic function and expression of H7
a by normal
Figure 4. Persistence of H7
a-specific CD8
+ memory T cells. We studied four experimental groups: i) B10.H7
b and B10 mice successfully treated
for melanoma as described in Fig. 1 (+B16.F10); ii) euthymic and thymectomized (Tx) B10 mice that underwent the same protocol excepting injection
of melanoma cells on day 0. On day 100, we sacrificed 3 mice per group and stained cell suspensions from spleen and bone marrow with H7
a
tetramers and antibodies against CD8 and CD44. A) Dot plots of one representative experiment out of three (gated on CD8 cells). B) Proportion and
absolute number of H7
a-specific T cells in recipients’ spleen and bone marrow (2 tibiae and femurs). Histograms represent the mean6SD of 3 mice
per group. Inserts depict CD44 expression on tetramer
+ CD8 T cells found in euthymic B10.H7
b and thymectomized B10 hosts. MFI: mean
fluorescence intensity.
doi:10.1371/journal.pone.0004116.g004
Fate of H7
a-Specific T Cells
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a-specific memory T cells were abundant in euthymic
B10.H7
b hosts, present in low numbers in thymectomized B10
hosts, and undetectable in euthymic B10 hosts.
Challenge of Hematopoietic Chimeras with Tumor Cells
No melanoma recurrence was seen in B10 mice (n=30)
observed for 6 months after induction of complete remission by
adoptive transfer of anti-H7
a T cells ([7] and data not shown). To
test whether lack of tumor relapse might be due to persistence of
H7
a-specific T cells at levels below the detection limit of tetramer-
staining assays, cured B10 recipients were challenged on day 100,
with 2610
5 melanoma cells (as on day 0). In euthymic cured B10
recipients, tumors grew rapidly (Fig. 5) and no accumulation of
H7
a-specific T cells was detected in the spleen, bone marrow or
tumor (Fig. 6). Thus, cured euthymic B10 mice did not show any
functional evidence of immune reactivity to H7
a or to any tumor-
associated epitopes. In thymectomized B10 hosts, a minimal
accumulation of H7
a-specific T cells was found (Fig. 6) that
entailed only a small delay in tumor growth (Fig. 5). Hence, H7
a-
specific memory T cells present in thymectomized B10 hosts were
unable to provide a protective antitumor response. In contrast,
H7
a-specific memory T cells present in B10.H7
b hosts generated a
strong anamnestic response following tumor rechallenge (Fig. 6).
In the latter mice, the tumor grew for a few days and then
disappeared (Fig. 5). Thus, H7
a-specific memory T cells found in
B10.H7
b hosts were perfectly functional.
Discussion
Intratumoral Accumulation of H7
a-Specific T Cells
A major obstacle encountered in cancer immunotherapy trials,
including those targeting MiHAs, is the failure of antigen-reactive T
cells to invade tumors and persist long-term [12,32–34]. Few studies
have addressed the in vivo fate of MiHA-specific T cells using MHC-
peptide tetramers [35,36]. Moreover, to the best of our knowledge,
no study has evaluated the in vivo fate of antigen-primed MiHA-
specific T cells, nor their behavior in the tumor environment. We
previously reported that adoptively transferred anti-H7
a Tc e l l sw e r e
found in large numbers in regressing melanomas (day 19) [7]. Here,
by looking at earlier time points, we found that selective tumor
infiltration by anti-H7
a T cells was established by day 3 after adoptive
transfer. Preferential localization of adoptively transferred CD8 T
cells to tumor sites has been reported in one clinical trial [37].
Homing to the tumor is probably due to interaction between
activated T cells and antigen-independent inflammatory ligands such
asVcam-1[7,38].Wefoundthatfollowinginitialseeding,numbersof
H7
a-specific T cells increased dramatically in the tumor but not the
spleen. Furthermore, based on CFSE profiles, we found that H7
a-
specific T cells in the tumor had divided much more extensively than
those in the spleen. These data suggest that the massive accumulation
of H7
a-specific T cells in the tumor between day 10 and day 15 is due
to in situ proliferation. They are also consistent with the fact that
differentiation and survival of primed CD8 (but not CD4) effector T
cells are independent of secondary lymphoid organs in adoptive hosts
[39]. However, we cannot formally discard the possibility that, in our
model, H7
a-specific T cells proliferate in the draining lymph node
and then migrate to the tumor. Further studies are needed to
understand the nature of signals that drive intratumoral expansion of
MiHA-specificT cells.Wespeculate that IFN-c may be an important
player in this process. Indeed, the local release of IFN-c by anti-H7
a
T cells upregulates expression of MHC I and H7
a in the tumor [7],
and may thereby stimulate proliferation of anti-H7
a Tc e l l s .
Nonetheless, though the tumor environment may not be particularly
propitious to T-cell invasion and expansion [9–12], the present work
illustrates that this limitation may be overcome by adoptive transfer of
primed CD8 T cells targeted to an immunodominant MiHA. In line
with this, new promising methods have been recently developed to
generate high avidity MiHA-specific CD8 T cells for adoptive
immunotherapy in human [40–42].
Relapse-Free Survival Did Not Necessitate Persistence of
H7
a-Reactive Memory T Cells
Whether long-term cancer remission induced by MiHA-
targeted T cells is associated with total eradication of cancer cells
or with persistence of low numbers of resting or slow growing
tumor cells (tumor dormancy) is unknown. The distinction
between these two outcomes is important since tumor persistence
always entails the risk of relapse. Genuine cancer cure requires
elimination of cancer stem cells which have a mostly quiescent cell
cycle profile and are capable of self-renewal. The quiescent status
of cancer stem cells renders them difficult to eradicate with
chemotherapy that typically target proliferating cells. Nonetheless,
T cells can eliminate quiescent cells as well as cycling cells. Thus,
when cultured with acute myeloid leukemia cells, MiHA-specific T
cells can wipe out leukemia stem cells [43]. Nevertheless, a
substantial body of evidence suggests that remissions induced by
various types of immunotherapy targeted to tumor specific
antigens (but not to MiHAs) are usually associated with tumor
Figure 5. Challenge of long-term chimeras with melanoma
cells. We studied mice from the four experimental groups described in
Fig. 4. On day 100, mice were challenged with 2610
5 B16.F10
melanoma cells s.c. A) Tumor surface area and B) survival of
experimental groups (n$10 mice per group). The mean survival times
for the following groups were significantly different: white vs. black,
white vs. red, and blue vs. black, P,0.0001; red vs. black, P,0.001. C)
Examination of excised tumor injection site shows large tumor nodules
(black) in B10 mice but only an inconspicuous micro-nodule in the
B10.H7
b mouse (one representative experiment out of 10). Tx,
thymectomized.
doi:10.1371/journal.pone.0004116.g005
Fate of H7
a-Specific T Cells
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a T cells
disappeared (euthymic B10 mice) nevertheless remained tumor-
free. The latter mice behave as naive mice when rechallenged with
melanoma cells. Thus, in this model, cure is probably due to
eradication of clonogenic tumor cells rather than to induction of
T-cell dependent tumor dormancy. Notably, we have observed no
late relapses in mice with EL4 leukemia treated with anti-H7
a T
cells ([6] and unpublished observations). This suggests that the
findings reported herein may not be unique to melanoma and may
be relevant to some rapidly growing tumors like B16.F10 and EL4.
By no means, however, do we infer that persistence of memory T
cells is generally irrelevant in adoptive cancer immunotherapy.
The occurrence of late leukemia relapses following allogeneic
hematopoietic cell transplantation argues against this view.
Nevertheless, the lack of cancer relapse in mice devoid of anti-
H7
a memory T cells illustrates the potency of the acute anti-tumor
effect that can be generated by anti-MiHA T cells.
Antigen Distribution and Thymus Function Regulate
Long-Term Persistence of H7
a-Specific Memory T Cells
Functional anti-H7
a T cells persisted long-term in B10.H7
b but
not B10 mice. The ubiquitous expression of H7
a on B10 host cells
led to physical demise or functional impairment of anti-H7
a T
cells. The exhaustion of H7
a-specific T cells in B10 recipients was
similar to that of anti-viral T cells confronted with viruses that
disseminate widely [45]. Thus, at least in euthymic subjects,
adoptively transferred host-reactive T cells should have a longer
life span when targeted to tissue-restricted (e.g., tumor-specific) as
opposed to ubiquitous epitopes. Assuming that prolonged
persistence of adoptively transferred T cells is probably relevant
Figure 6. Anti-H7
a T-cell response following tumor challenge. We studied mice from the four experimental groups described in Fig. 4. On day
100, we challenged mice with 2610
5 B16.F10 melanoma cells s.c. Mice were sacrificed on day 126 and cell suspensions from their spleen, bone
marrow and tumor were stained with H7
a tetramers and anti-CD8 antibody. A) Dot plots of one representative experiment out of three (gated on CD8
cells). B) Proportion and absolute number of H7
a-specific T cells in recipients’ spleen, bone marrow (2 tibiae and femurs) and tumor on day 126.
Results are depicted as the mean6SD of 3 mice per group. Absolute numbers of H7
a-specific T cells in the three sites were higher in thymectomized
relative to euthymic B10 hosts (0.02,P,0.002), and were higher in B10.H7
b than in euthymic (P,0.0005) or thymectomized (P,0.01) B10 hosts. Tx,
thymectomized.
doi:10.1371/journal.pone.0004116.g006
Fate of H7
a-Specific T Cells
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advantageous to target MiHAs with a restricted tissue distribution.
Fortunately, several non ubiquitous MiHAs have been discovered
in human [46–48]. Accordingly, MiHAs derived from oncopro-
teins, such as HA-1, represent particularly attractive targets for
adoptive immunotherapy of hematopoietic malignancies and solid
tumors [49,50]. Finally, we found that thymic output had a
negative impact on persistence of H7
a-specific memory T cells.
Many cancer patients, particularly those in older age groups,
present thymic insufficiency [51]. MiHA-specific T cells may have
a more protracted survival in these subjects. From a different
perspective, the concept that thymic output mitigates the
persistence of MiHA-reactive T cells could explain why graft-
versus-host disease becomes more frequent with increasing
recipient age following conventional allogeneic hematopoietic cell
transplantation [52,53].
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